These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3807367)

  • 1. Aromatase inhibitors and their potential clinical significance.
    Brodie AM; Wing LY; Goss P; Dowsett M; Coombes RC
    J Steroid Biochem; 1986 Nov; 25(5B):859-65. PubMed ID: 3807367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aromatase inhibitors and the treatment of breast cancer.
    Brodie AM; Wing LY; Goss P; Dowsett M; Coombes RC
    J Steroid Biochem; 1986 Jan; 24(1):91-7. PubMed ID: 3702431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aromatase inhibitors: basic and clinical studies.
    Brodie AM; Coombes RC; Dowsett M
    J Steroid Biochem; 1987; 27(4-6):899-903. PubMed ID: 3320568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of aromatase inhibitor 4-hydroxyandrostenedione and other compounds in the 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma model.
    Brodie AM; Garrett WM; Hendrickson JR; Tsai-Morris CH
    Cancer Res; 1982 Aug; 42(8 Suppl):3360s-3364s. PubMed ID: 6805949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatase and its inhibitors--an overview.
    Brodie A
    J Steroid Biochem Mol Biol; 1991; 40(1-3):255-61. PubMed ID: 1958529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of treatment with aromatase inhibitor 4-hydroxandrostenedione on the nonhuman primate menstrual cycle.
    Brodie AM; Hammond JO; Ghosh M; Meyer K; Albrecht ED
    Cancer Res; 1989 Sep; 49(17):4780-4. PubMed ID: 2758411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential responses of sex steroid target tissues of rats treated with 4-hydroxyandrostenedione.
    Wing LY; Hammond JO; Brodie AM
    Endocrinology; 1988 Jun; 122(6):2418-27. PubMed ID: 3131115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aromatase and other inhibitors in breast and prostatic cancer.
    Brodie AM; Banks PK; Inkster SE; Son C; Koos RD
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1043-8. PubMed ID: 2285580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase inhibitors and hormone-dependent cancers.
    Brodie AM; Banks PK; Inkster SE; Dowsett M; Coombes RC
    J Steroid Biochem Mol Biol; 1990 Nov; 37(3):327-33. PubMed ID: 2257237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of aromatase inhibitor 4-hydroxyandrostenedione on steroid receptors in hormone-dependent tissues of the rat.
    Zhou JL; Brodie A
    J Steroid Biochem Mol Biol; 1995 Jan; 52(1):71-6. PubMed ID: 7857875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of aromatase inhibitors, aminoglutethimide, and 4-hydroxyandrostenedione on cyclic rats and rats with 7,12-dimethylbenz(a)anthracene-induced mammary tumors.
    Wing LY; Garrett WM; Brodie AM
    Cancer Res; 1985 Jun; 45(6):2425-8. PubMed ID: 3921242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.
    Dowsett M; Goss PE; Powles TJ; Hutchinson G; Brodie AM; Jeffcoate SL; Coombes RC
    Cancer Res; 1987 Apr; 47(7):1957-61. PubMed ID: 3815384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase inhibitors in the treatment of breast cancer.
    Brodie AM
    J Steroid Biochem Mol Biol; 1994 Jun; 49(4-6):281-7. PubMed ID: 8043490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors prevent granulosa cell differentiation: an obligatory role for estrogens in luteinizing hormone receptor expression.
    Knecht M; Brodie AM; Catt KJ
    Endocrinology; 1985 Sep; 117(3):1156-61. PubMed ID: 2990868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of in vivo administration of 10-propargylestr-4-ene-3,17-dione on rat ovarian aromatase and estrogen levels.
    Brandt ME; Covey DF; Zimniski SJ
    J Enzyme Inhib; 1990; 4(2):143-52. PubMed ID: 2098521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report.
    Goss PE; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Gazet JC; Coombes RC
    Cancer Res; 1986 Sep; 46(9):4823-6. PubMed ID: 2942241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.
    Dowsett M; Stein RC; Coombes RC
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):155-9. PubMed ID: 1388047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo studies with aromatase inhibitor 4-hydroxy-androstenedione.
    Brodie AM; Wing LY
    Steroids; 1987; 50(1-3):89-103. PubMed ID: 3504069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors.
    Nishino Y; Schneider MR; Michna H; el Etreby MF
    J Steroid Biochem; 1989; 34(1-6):435-7. PubMed ID: 2533949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer.
    Lønning PE; Dowsett M; Powles TJ
    J Steroid Biochem; 1990 Mar; 35(3-4):355-66. PubMed ID: 2139151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.